Zacks Investment Research upgraded shares of Catalent (NYSE:CTLT) from a sell rating to a hold rating in a research note issued to investors on Tuesday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
A number of other brokerages have also recently weighed in on CTLT. Needham & Company LLC reiterated a hold rating on shares of Catalent in a report on Monday, October 23rd. BidaskClub raised Catalent from a hold rating to a buy rating in a research report on Thursday, October 5th. First Analysis initiated coverage on Catalent in a research report on Friday, January 5th. They issued an equal weight rating on the stock. ValuEngine lowered Catalent from a buy rating to a hold rating in a research report on Monday, October 2nd. Finally, Piper Jaffray Companies raised their price objective on Catalent from $45.00 to $50.00 and gave the company an overweight rating in a research report on Tuesday, November 7th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $44.44.
Catalent (NYSE:CTLT) last issued its earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. During the same quarter last year, the firm earned $0.16 earnings per share. The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. analysts predict that Catalent will post 1.47 EPS for the current fiscal year.
In other Catalent news, Director Uwe Roehrhoff bought 7,500 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were acquired at an average cost of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Advisor Group Inc. increased its position in shares of Catalent by 1.3% during the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after acquiring an additional 65 shares during the last quarter. Stifel Financial Corp increased its position in shares of Catalent by 0.9% during the second quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after acquiring an additional 96 shares during the last quarter. People s United Financial Inc. increased its position in shares of Catalent by 1.9% during the second quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock worth $665,000 after acquiring an additional 356 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Catalent by 12.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after acquiring an additional 559 shares during the last quarter. Finally, Acrospire Investment Management LLC increased its position in shares of Catalent by 72.2% during the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after acquiring an additional 1,300 shares during the last quarter. 99.37% of the stock is currently owned by institutional investors and hedge funds.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.